Drug Trial Radar · NCT03306264
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
Last checked: Nov 20, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
227
Actual
Start
Feb 15, 2018
Primary completion
Sep 10, 2021
Study completion May 25, 2023
Sponsor
- Lead sponsor
- Astex Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 11, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter PK study of ASTX727 versus IV decitabine. Adult participants who were candidates to receive IV decitabine were randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine 20 mg/m\^2 Daily×5 in Cycle 2, or the converse order. After completion of PK studies during the first 2 treatment cycles, participants continued to receive treatment with ASTX727 from Cycle 3 onward (in 28-day cycles) until disease progression, unacceptable toxicity, or the participants discontinued treatment or withdrew from the study.
Conditions
- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia
- Acute Myeloid Leukemia
Interventions
ASTX727Drug
ASTX727 oral tablet
DacogenDrug
Decitabine 20 mg/m\^2 one-hour IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total 5-day Area Under the Curve From 0 to 24 Hours (AUC0-24) After Treatment With ASTX727 And IV DecitabineTime frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)
Locations
84 sites in 10 countries. Site status is shown where the registry gives one.
Pinnacle Research Group
Anniston, Alabama
Mayo Clinic Arizona
Phoenix, Arizona
Arizona Clinical Research Center
Tucson, Arizona
Compassionate Cancer Care Research Group
Fountain Valley, California
University of Southern California
Los Angeles, California
Yale
New Haven, Connecticut
Georgetown University
Washington D.C., District of Columbia
Boca Raton Clinical Research
Boca Raton, Florida
Holy Cross Hospital
Fort Lauderdale, Florida
Mount Sinai
Miami Beach, Florida
Rush University Medical Center
Chicago, Illinois
University of Chicago
Chicago, Illinois
Quincy Medical Group
Quincy, Illinois
Indiana Blood and Marrow Transplantation
Indianapolis, Indiana
Norton Cancer Institute
Louisville, Kentucky
Johns Hopkins
Baltimore, Maryland
Regional Cancer Care Associates
Bethesda, Maryland
Michigan Center of Medical Research
Farmington Hills, Michigan
Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
Hackensack
Hackensack, New Jersey
Roswell Park
Buffalo, New York
Monter Cancer Center
Lake Success, New York
Weill Cornell Medicine
New York, New York
Montefiore
The Bronx, New York
Gabrail Cancer Center
Canton, Ohio
Ohio State University
Columbus, Ohio
Oregon Health & Sciences University
Portland, Oregon
West Penn Allegheny Cancer Institute
Pittsburgh, Pennsylvania
University of Pittsburgh Hillman Cancer Center
Pittsburgh, Pennsylvania
Charleston Hematology Oncology Associates
Charleston, South Carolina
Vanderbilt
Nashville, Tennessee
Baylor Scott & White University Medical Center
Dallas, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
Houston Methodist Cancer Center
Houston, Texas
MD Anderson Cancer Center
Houston, Texas
Utah Cancer Specialists
Salt Lake City, Utah
Kadlec Clinic Hematology and Oncology
Kennewick, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington
Uniklinikum Salzburg
Salzburg, Austria
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.